Cash Flow Statement
Growth Metrics

Mimedx (MDXG) EBT Margin (2011 - 2026)

Mimedx recorded quarterly EBT Margin of 25.99% in Q1 2026, down 240.82% quarter-over-quarter from 18.46% in Q4 2025, and down 3575.0% year-over-year from 0.75% in Q1 2025.

Mimedx's EBT Margin history runs 16 years deep, the most recent figure standing at 25.99% for Q1 2026.

  • In Q1 2026, EBT Margin fell 3575.0% year-over-year to 25.99%; the TTM figure through Mar 2026 stood at 10.87% (down 460.0% YoY), while the FY2025 annual figure was 15.83%, down 59.0% from the prior year.
  • EBT Margin came in at 25.99% for Q1 2026 at Mimedx, down from 18.46% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 26.62% in Q2 2024 to a low of 25.99% in Q1 2026.
  • A 5-year average of 6.15% and a median of 12.11% in 2024 frame the typical range for EBT Margin.
  • Across the five-year window, EBT Margin surged 2745 bps in 2023 and sank 3575 bps in 2026, its largest moves.
  • Mimedx's EBT Margin stood at 13.25% in 2022, then increased by 21 bps to 16.02% in 2023, then decreased by 24 bps to 12.11% in 2024, then soared by 52 bps to 18.46% in 2025, then sank by 241 bps to 25.99% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods registered 25.99%, 18.46%, and 20.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn -25.99%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -25.99%
Dec 31, 2025 18.46%
Sep 30, 2025 20.09%
Jun 30, 2025 13.19%
Mar 31, 2025 9.76%
Dec 31, 2024 12.11%
Sep 30, 2024 13.58%
Jun 30, 2024 26.62%
Mar 31, 2024 13.47%
Dec 31, 2023 16.02%
Sep 30, 2023 11.54%
Jun 30, 2023 11.29%
Mar 31, 2023 -2.64%
Dec 31, 2022 13.25%
Sep 30, 2022 -12.37%
Jun 30, 2022 -16.16%
Mar 31, 2022 -17.70%
Dec 31, 2021 0.18%
Sep 30, 2021 -3.23%
Jun 30, 2021 -2.62%
Mar 31, 2021 -13.88%
Dec 31, 2020 -25.68%
Sep 30, 2020 -30.14%
Jun 30, 2020 -15.73%
Mar 31, 2020 -26.12%
Dec 31, 2019 -9.50%
Sep 30, 2019 13.58%
Jun 30, 2019 -25.46%
Mar 31, 2019 -19.88%
Dec 31, 2018 -9.43%
Sep 30, 2018 0.54%
Jun 30, 2018 1.88%
Mar 31, 2018 3.64%
Dec 31, 2017 21.52%
Sep 30, 2017 15.56%
Jun 30, 2017 8.78%
Mar 31, 2017 8.78%
Dec 31, 2016 -12.78%
Sep 30, 2016 7.16%
Jun 30, 2016 6.02%
Mar 31, 2016 2.64%
Dec 31, 2015 14.82%
Sep 30, 2015 13.69%
Jun 30, 2015 12.38%
Mar 31, 2015 10.38%
Dec 31, 2014 11.73%
Sep 30, 2014 11.10%
Jun 30, 2014 -1.56%
Mar 31, 2014 -4.66%
Dec 31, 2013 -7.91%
Sep 30, 2013 -1.62%
Jun 30, 2013 -5.60%
Mar 31, 2013 -13.59%
Dec 31, 2012 -15.28%
Sep 30, 2012 -53.05%
Jun 30, 2012 -15.23%
Mar 31, 2012 -29.51%
Dec 31, 2011 -97.79%
Sep 30, 2011 -82.05%
Jun 30, 2011 -129.76%
Mar 31, 2011 -320.81%